Related Experiment Video
Updated: Mar 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy
Mariasanta Napolitano1, Sergio Siragusa2, Guglielmo Mariani3
1Hematology Unit-Reference Regional Center for Thrombosis and Hemostasis, Università di Palermo, 90127 Palermo, Italy. mariasanta.napolitano@unipa.it.
Factor VII deficiency, a common inherited bleeding disorder, presents varied symptoms despite plasma levels. Management requires assessing multiple factors for accurate treatment and prophylaxis strategies.
Area of Science:
- Hematology
- Genetics
- Internal Medicine
Background:
- Factor VII deficiency is a rare autosomal recessive bleeding disorder.
- It is characterized by a lack of correlation between Factor VII plasma levels and bleeding severity.
- Clinical presentations range from asymptomatic to life-threatening hemorrhages.
Purpose of the Study:
- To provide an updated summary of Factor VII deficiency.
- To review the clinical phenotype, laboratory diagnosis, and treatment of inherited Factor VII deficiency.
Main Methods:
- Literature review of clinical studies and case reports.
- Analysis of diagnostic criteria and treatment guidelines.
- Synthesis of current knowledge on Factor VII deficiency management.
Main Results:
- Factor VII deficiency exhibits a wide spectrum of clinical phenotypes.
- Diagnosis relies on a combination of clinical evaluation and laboratory tests.
- Treatment strategies include factor replacement therapy and prophylaxis.
Conclusions:
- Effective management of Factor VII deficiency necessitates a comprehensive approach.
- Individualized treatment plans are crucial for optimizing patient outcomes.
- Further research is needed to improve risk prediction and prophylactic strategies.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

